Black Rock Inc. Transcode Therapeutics, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.31 - $0.91 $4,430 - $13,006	-14,293 Reduced 91.17%	1,385 $0
Q4 2022 Feb 13, 2023	BUY	$0.33 - $984.0 $113 - $338,496	344 Added 2.24%	15,678 $10,000
Q3 2022 Nov 14, 2022	SELL	$1.01 - $952.0 $434 - $409,360	-430 Reduced 2.73%	15,334 $17,000
Q2 2022 Aug 12, 2022	SELL	$1.2 - $3.03 $309 - $781	-258 Reduced 1.61%	15,764 $20,000
Q1 2022 May 12, 2022	SELL	$2.03 - $3.01 $1,571 - $2,329	-774 Reduced 4.61%	16,022 $46,000
Q4 2021 Feb 10, 2022	BUY	$2.42 - $3.41 $1,040 - $1,466	430 Added 2.63%	16,796 $43,000
Q3 2021 Nov 09, 2021	BUY	$2.37 - $6.45 $38,787 - $105,560	16,366 New	16,366 $49,000

6.5K

Ticker RNAZ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,977,200
Market Cap $6.1M
Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.